BR112015023725A2 - composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme - Google Patents
composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filmeInfo
- Publication number
- BR112015023725A2 BR112015023725A2 BR112015023725A BR112015023725A BR112015023725A2 BR 112015023725 A2 BR112015023725 A2 BR 112015023725A2 BR 112015023725 A BR112015023725 A BR 112015023725A BR 112015023725 A BR112015023725 A BR 112015023725A BR 112015023725 A2 BR112015023725 A2 BR 112015023725A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage composition
- film dosage
- self
- formation process
- supporting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
resumo composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme a presente invenção refere-se aos produtos e métodos para o tratamento de de vários sintomas em um paciente, incluindo tratamento de dor sofrida por um paciente. a invenção particularmente refere-se às formas de dosagem autossuportantes que fornecem um agente ativo enquanto fornecem adesão bucal suficiente da forma de dosagem. além disso, a presente invenção fornece uma forma de dosagem que é útil em reduzir a probabilidade de abuso de desvio do agente ativo. 1/1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/842,543 US20140271788A1 (en) | 2013-03-15 | 2013-03-15 | Sublingual and buccal film compositions |
| US14/196,082 US9511033B2 (en) | 2013-03-15 | 2014-03-04 | Sublingual and buccal film compositions |
| PCT/US2014/028568 WO2014144241A1 (en) | 2013-03-15 | 2014-03-14 | Sublingual and buccal film compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015023725A2 true BR112015023725A2 (pt) | 2017-07-18 |
Family
ID=51528033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023725A BR112015023725A2 (pt) | 2013-03-15 | 2014-03-14 | composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20140271788A1 (pt) |
| EP (1) | EP2968121B1 (pt) |
| JP (2) | JP6448096B2 (pt) |
| KR (1) | KR20160029730A (pt) |
| CN (1) | CN105491997B (pt) |
| AU (1) | AU2014227693B2 (pt) |
| BR (1) | BR112015023725A2 (pt) |
| CA (1) | CA2906773C (pt) |
| DK (1) | DK2968121T3 (pt) |
| IL (1) | IL241441B (pt) |
| MX (1) | MX2015013184A (pt) |
| MY (1) | MY181159A (pt) |
| RU (1) | RU2015143647A (pt) |
| WO (1) | WO2014144241A1 (pt) |
| ZA (1) | ZA201507685B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271788A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| NZ731309A (en) | 2014-11-07 | 2022-02-25 | Indivior Uk Ltd | Buprenorphine dosing regimens |
| WO2016105563A1 (en) * | 2014-12-23 | 2016-06-30 | Arx, Llc | Method of producing uniform buprenorphine-containing formulations |
| US20180104183A1 (en) * | 2015-04-07 | 2018-04-19 | Nipro Corporation | Oral film preparation |
| CN108697700B (zh) | 2016-02-04 | 2021-08-17 | 辛多美制药有限公司 | 氘代多潘立酮组合物和用于治疗病症的方法 |
| CN109496153B (zh) | 2016-05-28 | 2024-04-23 | 印度政府生物技术部独立机构拉吉夫甘地生物技术中心 | 作为肝细胞癌治疗剂的龙葵皂苷b及其衍生物 |
| IL266537B2 (en) | 2016-11-15 | 2023-12-01 | Klaria Pharma Holding Ab | pharmaceutical preparation |
| CN110337290A (zh) | 2016-12-31 | 2019-10-15 | 比奥克斯塞尔医疗股份有限公司 | 舌下右旋美托咪啶用于治疗激越的用途 |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
| EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| CN112368023A (zh) * | 2018-06-14 | 2021-02-12 | 株式会社钟化 | 包含药物活性成分的制剂 |
| AU2019295699A1 (en) * | 2018-06-27 | 2021-01-28 | Arx, Llc | Film formulations containing dexmedetomidine and methods of producing them |
| JP7365409B2 (ja) * | 2018-06-28 | 2023-10-19 | エイアールエックス エルエルシー | 溶解性単位用量膜構造物を製造するための分配方法 |
| JP7287032B2 (ja) | 2019-03-20 | 2023-06-06 | 株式会社リコー | シート、シート積層体、医薬品、シートの製造方法、及びシート積層体の製造方法 |
| JP2022540706A (ja) | 2019-07-19 | 2022-09-16 | バイオエクセル セラピューティクス，インコーポレイテッド | 鎮静作用のないデクスメデトミジン治療レジメン |
| US11806320B2 (en) * | 2020-02-19 | 2023-11-07 | Endo Ventures Limited | Isoproterenol compositions and methods |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3493657A (en) | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
| US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
| US4366159A (en) | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
| GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US5223507A (en) | 1992-01-21 | 1993-06-29 | G. D. Searle & Co. | Method of using opioid compounds as delta opioid selective agonist analgesics |
| US5225417A (en) | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
| GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| CA2197554A1 (en) | 1994-09-19 | 1996-03-28 | The Du Pont Merck Pharmaceutical Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| AT403162B (de) | 1995-10-11 | 1997-11-25 | Nycomed Austria Gmbh | Neue kristallform von morphin-6-glucuronid |
| DE19602961A1 (de) | 1995-12-20 | 1997-07-31 | Nycomed Arzneimittel Gmbh | Neue Dihydromorphinderivate, Verfahren zu deren Herstellung und deren Verwendung |
| PT914097E (pt) | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
| HU224964B1 (en) | 1997-02-14 | 2006-04-28 | Goedecke Ag | Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone |
| PT948965E (pt) | 1997-07-11 | 2004-08-31 | Toray Industries | Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano |
| EP0913152B1 (de) | 1997-11-03 | 2001-12-19 | Stada Arzneimittel Ag | Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum |
| IT1302682B1 (it) | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
| US20110033542A1 (en) * | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US20140271788A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| WO2005004989A2 (en) * | 2003-07-01 | 2005-01-20 | Todd Maibach | Film comprising therapeutic agents |
| EP1750675B1 (en) | 2004-06-02 | 2008-10-29 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and salt thereof |
| US20060046962A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| WO2006026713A2 (en) * | 2004-08-31 | 2006-03-09 | Tracie Martyn International, Llc | Topical benfotiamine and pyridoxamine compositions |
| JP2007304673A (ja) | 2006-05-09 | 2007-11-22 | Kyocera Mita Corp | 監視装置及び監視システム並びに監視プログラム |
| US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
-
2013
- 2013-03-15 US US13/842,543 patent/US20140271788A1/en not_active Abandoned
-
2014
- 2014-03-04 US US14/196,082 patent/US9511033B2/en active Active
- 2014-03-14 EP EP14721650.1A patent/EP2968121B1/en active Active
- 2014-03-14 MY MYPI2015703198A patent/MY181159A/en unknown
- 2014-03-14 CA CA2906773A patent/CA2906773C/en active Active
- 2014-03-14 WO PCT/US2014/028568 patent/WO2014144241A1/en active Application Filing
- 2014-03-14 RU RU2015143647A patent/RU2015143647A/ru not_active Application Discontinuation
- 2014-03-14 KR KR1020157028424A patent/KR20160029730A/ko not_active Application Discontinuation
- 2014-03-14 JP JP2016502836A patent/JP6448096B2/ja active Active
- 2014-03-14 CN CN201480027179.8A patent/CN105491997B/zh active Active
- 2014-03-14 DK DK14721650.1T patent/DK2968121T3/en active
- 2014-03-14 MX MX2015013184A patent/MX2015013184A/es unknown
- 2014-03-14 AU AU2014227693A patent/AU2014227693B2/en active Active
- 2014-03-14 BR BR112015023725A patent/BR112015023725A2/pt not_active Application Discontinuation
-
2015
- 2015-09-10 IL IL241441A patent/IL241441B/en active IP Right Grant
- 2015-10-14 ZA ZA2015/07685A patent/ZA201507685B/en unknown
-
2016
- 2016-12-05 US US15/369,101 patent/US20170296482A1/en not_active Abandoned
-
2018
- 2018-10-09 US US16/155,100 patent/US20190038570A1/en not_active Abandoned
- 2018-11-30 JP JP2018225191A patent/JP2019048882A/ja not_active Abandoned
-
2019
- 2019-12-06 US US16/705,422 patent/US20200315984A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9511033B2 (en) | 2016-12-06 |
| IL241441B (en) | 2019-07-31 |
| US20170296482A1 (en) | 2017-10-19 |
| CA2906773A1 (en) | 2014-09-18 |
| AU2014227693A1 (en) | 2015-10-29 |
| CN105491997A (zh) | 2016-04-13 |
| WO2014144241A1 (en) | 2014-09-18 |
| CA2906773C (en) | 2023-12-12 |
| US20140271789A1 (en) | 2014-09-18 |
| US20200315984A1 (en) | 2020-10-08 |
| JP6448096B2 (ja) | 2019-01-09 |
| DK2968121T3 (en) | 2019-02-04 |
| RU2015143647A (ru) | 2017-04-21 |
| US20140271788A1 (en) | 2014-09-18 |
| KR20160029730A (ko) | 2016-03-15 |
| JP2019048882A (ja) | 2019-03-28 |
| EP2968121A1 (en) | 2016-01-20 |
| JP2016513736A (ja) | 2016-05-16 |
| CN105491997B (zh) | 2019-12-17 |
| IL241441A0 (en) | 2015-11-30 |
| MX2015013184A (es) | 2016-04-07 |
| MY181159A (en) | 2020-12-19 |
| AU2014227693B2 (en) | 2018-06-21 |
| EP2968121B1 (en) | 2018-12-19 |
| US20190038570A1 (en) | 2019-02-07 |
| ZA201507685B (en) | 2017-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023725A2 (pt) | composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| PH12015502302A1 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
| BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| BR112018014467A2 (pt) | tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| FI20115165A0 (fi) | Terapeuttisia ja diagnostisia menetelmiä | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| BR112016012248A2 (pt) | método de tratamento de nefropatia | |
| BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes | |
| BR112018069174A2 (pt) | tratamento de prurido urêmico | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| BR112016014099A2 (pt) | método de tratamento de feridas | |
| BR112015026805A2 (pt) | métodos e tratamento para determinadas desordens baseadas em dismielinização e desmielinização e/ ou promoção da remielinização | |
| BR112016014617A2 (pt) | Variante do fator xa (fxa) e usos da referida variante | |
| BR112016013923A2 (pt) | Modulador de cetp para o uso no tratamento de enfermidade ocular | |
| BR112015023463A2 (pt) | uso de sedoeptulose para prevenção ou tratamento de inflamação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: AQUESTIVE THERAPEUTICS, INC. (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |